UA77153C2 - Method for determining the presence of leptin and leptinomimetic - Google Patents

Method for determining the presence of leptin and leptinomimetic Download PDF

Info

Publication number: UA77153C2
Authority: UA; Ukraine
Prior art keywords: leptin; promoter; cell; apd; cell line
Prior art date: 1999-10-11

Application number

UA2002053825A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-11

Filing date

2000-05-10

Publication date

2006-11-15

2000-05-10 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

2006-11-15 Publication of UA77153C2 publication Critical patent/UA77153C2/uk

Links

102000016267 Leptin Human genes 0.000 title claims abstract description 100
108010092277 Leptin Proteins 0.000 title claims abstract description 100
229940039781 leptin Drugs 0.000 title claims abstract description 100
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title claims abstract description 100
238000000034 method Methods 0.000 title claims abstract description 26
239000013598 vector Substances 0.000 claims abstract description 17
239000002773 nucleotide Substances 0.000 claims abstract description 6
125000003729 nucleotide group Chemical group 0.000 claims abstract description 6
210000004027 cell Anatomy 0.000 claims description 53
108010048036 Angiopoietin-2 Proteins 0.000 claims description 36
102000009075 Angiopoietin-2 Human genes 0.000 claims description 35
238000012216 screening Methods 0.000 claims description 20
108700008625 Reporter Genes Proteins 0.000 claims description 16
230000004044 response Effects 0.000 claims description 15
230000004913 activation Effects 0.000 claims description 13
210000001789 adipocyte Anatomy 0.000 claims description 12
239000001963 growth medium Substances 0.000 claims description 10
108700039691 Genetic Promoter Regions Proteins 0.000 claims description 9
238000002965 ELISA Methods 0.000 claims description 8
241001529936 Murinae Species 0.000 claims description 7
210000003527 eukaryotic cell Anatomy 0.000 claims description 6
230000014509 gene expression Effects 0.000 claims description 6
210000000229 preadipocyte Anatomy 0.000 claims description 6
238000003757 reverse transcription PCR Methods 0.000 claims description 5
238000010839 reverse transcription Methods 0.000 claims description 4
239000007790 solid phase Substances 0.000 claims description 4
210000004271 bone marrow stromal cell Anatomy 0.000 claims description 3
210000004748 cultured cell Anatomy 0.000 claims description 3
238000011534 incubation Methods 0.000 claims description 3
108091092328 cellular RNA Proteins 0.000 claims description 2
210000005260 human cell Anatomy 0.000 claims description 2
238000011002 quantification Methods 0.000 claims description 2
238000001890 transfection Methods 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims 1
238000007796 conventional method Methods 0.000 claims 1
238000003018 immunoassay Methods 0.000 claims 1
238000003752 polymerase chain reaction Methods 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 abstract description 14
238000004113 cell culture Methods 0.000 abstract description 3
238000006243 chemical reaction Methods 0.000 abstract description 3
230000003993 interaction Effects 0.000 abstract description 2
229920002477 rna polymer Polymers 0.000 abstract 1
238000004458 analytical method Methods 0.000 description 19
230000000694 effects Effects 0.000 description 12
230000009471 action Effects 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
239000000047 product Substances 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
102000005962 receptors Human genes 0.000 description 10
239000003446 ligand Substances 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 7
238000012360 testing method Methods 0.000 description 7
208000008589 Obesity Diseases 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
239000013641 positive control Substances 0.000 description 6
102000004127 Cytokines Human genes 0.000 description 5
108090000695 Cytokines Proteins 0.000 description 5
108091027981 Response element Proteins 0.000 description 5
238000013459 approach Methods 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
235000020824 obesity Nutrition 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
239000000126 substance Substances 0.000 description 5
101000732672 Mus musculus Angiopoietin-2 Proteins 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
230000012010 growth Effects 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
108060001084 Luciferase Proteins 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
230000008499 blood brain barrier function Effects 0.000 description 3
210000001218 blood-brain barrier Anatomy 0.000 description 3
108700010039 chimeric receptor Proteins 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
239000005090 green fluorescent protein Substances 0.000 description 3
108010019813 leptin receptors Proteins 0.000 description 3
239000002609 medium Substances 0.000 description 3
230000035772 mutation Effects 0.000 description 3
AYNDKKQQUZPETC-NXVVXOECSA-N (z)-2,3-bis(2,4,5-trimethylthiophen-3-yl)but-2-enedinitrile Chemical compound CC1=C(C)SC(C)=C1\C(C#N)=C(\C#N)C1=C(C)SC(C)=C1C AYNDKKQQUZPETC-NXVVXOECSA-N 0.000 description 2
-1 .-N. Chemical compound 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
102000003996 Interferon-beta Human genes 0.000 description 2
108090000467 Interferon-beta Proteins 0.000 description 2
102100031775 Leptin receptor Human genes 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
210000000577 adipose tissue Anatomy 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000001514 detection method Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000037149 energy metabolism Effects 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
230000037406 food intake Effects 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
230000006870 function Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000006698 induction Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
208000001022 morbid obesity Diseases 0.000 description 2
229940126619 mouse monoclonal antibody Drugs 0.000 description 2
239000000813 peptide hormone Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
BLCYCYHFLMGVPO-UHFFFAOYSA-N 2-(1h-benzimidazole-2-carbonyl)-3h-benzimidazole-5-carboximidamide Chemical compound C1=CC=C2NC(C(=O)C3=NC4=CC=C(C=C4N3)C(=N)N)=NC2=C1 BLCYCYHFLMGVPO-UHFFFAOYSA-N 0.000 description 1
108090000363 Bacterial Luciferases Proteins 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108090000331 Firefly luciferases Proteins 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
241000899793 Hypsophrys nicaraguensis Species 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
102100036721 Insulin receptor Human genes 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
101150118680 aflR gene Proteins 0.000 description 1
239000000556 agonist Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
235000019994 cava Nutrition 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000019771 cognition Effects 0.000 description 1
208000012696 congenital leptin deficiency Diseases 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000047825 human ANGPT2 Human genes 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
229960001388 interferon-beta Drugs 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
238000000185 intracerebroventricular administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
102000005861 leptin receptors Human genes 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
238000013116 obese mouse model Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000029865 regulation of blood pressure Effects 0.000 description 1
230000014493 regulation of gene expression Effects 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
201000007906 type 1 diabetes mellitus 2 Diseases 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
239000013603 viral vector Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Analytical Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Physics & Mathematics (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)

UA2002053825A 1999-10-11 2000-05-10 Method for determining the presence of leptin and leptinomimetic UA77153C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL13231399A IL132313A0 (en)	1999-10-11	1999-10-11	Leptin assay
PCT/IL2000/000621 WO2001027319A2 (fr)	1999-10-10	2000-10-05	Dosage de la leptine

Publications (1)

Publication Number	Publication Date
UA77153C2 true UA77153C2 (en)	2006-11-15

Family

ID=11073317

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002053825A UA77153C2 (en)	1999-10-11	2000-05-10	Method for determining the presence of leptin and leptinomimetic

Country Status (24)

Country	Link
US (1)	US7247427B1 (fr)
EP (1)	EP1222467B1 (fr)
JP (1)	JP2003511057A (fr)
KR (1)	KR100863580B1 (fr)
CN (1)	CN1159585C (fr)
AR (1)	AR025995A1 (fr)
AT (1)	ATE322017T1 (fr)
AU (1)	AU778727B2 (fr)
BR (1)	BR0014626A (fr)
CA (1)	CA2386365A1 (fr)
CY (1)	CY1105025T1 (fr)
DE (1)	DE60027031T2 (fr)
DK (1)	DK1222467T3 (fr)
EA (1)	EA004709B1 (fr)
EE (1)	EE200200189A (fr)
ES (1)	ES2256045T3 (fr)
HK (1)	HK1048514B (fr)
IL (2)	IL132313A0 (fr)
NO (1)	NO20021604D0 (fr)
PT (1)	PT1222467E (fr)
SI (1)	SI1222467T1 (fr)
UA (1)	UA77153C2 (fr)
WO (1)	WO2001027319A2 (fr)
ZA (1)	ZA200202155B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2372364A1 (fr) *	2010-03-31	2011-10-05	Medizinische Hochschule Hannover	Biomarqueur pour hypertension pulmonaire
PT2661266T (pt)	2011-01-07	2020-11-30	Anji Pharma Us Llc	Terapias com base em ligandos do recetor quimiossensorial
US9795792B2 (en)	2011-02-25	2017-10-24	Medtronic, Inc.	Emergency mode switching for non-pacing modes
CN102221615A (zh) *	2011-03-31	2011-10-19	广州华灿医药科技有限公司	一种基于Angiogenin检测的双抗夹心ELISA方法
SG10201901922VA (en)	2012-01-06	2019-04-29	Elcelyx Therapeutics Inc	Compositions and methods for treating metabolic disorders
MX2014008190A (es)	2012-01-06	2015-02-04	Elcelyx Therapeutics Inc	Composiciones de biguanida y métodos para tratar transtornos metabólicos.
WO2013158928A2 (fr)	2012-04-18	2013-10-24	Elcelyx Therapeutics, Inc.	Thérapies à base de ligand de récepteur chimiosensoriels
HK1210825A1 (en)	2012-07-11	2016-05-06	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CN102901823A (zh) *	2012-10-26	2013-01-30	安徽安科生物工程（集团）股份有限公司	瘦素检测试剂盒
EA039530B1 (ru)	2013-01-05	2022-02-08	Анджи Фарма (Юс) Элэлси	Композиция с отсроченным высвобождением, содержащая бигуанид
CN104459105B (zh) *	2014-12-05	2016-03-09	重庆中元生物技术有限公司	一种检测lp的胶乳增强免疫比浊试剂盒及其制备方法
CN115901697B (zh) *	2021-08-26	2026-03-17	苏州生物医药转化工程中心	一种检测瘦素相关蛋白或其类似物的活性的方法
CN114940717B (zh) *	2022-06-30	2024-04-26	武汉海特生物制药股份有限公司	嵌合受体、32d瘦素敏感细胞株及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0914611A4 (fr)	1996-04-22	2002-10-16	Merck & Co Inc	Dosage de la leptine

1999
- 1999-10-11 IL IL13231399A patent/IL132313A0/xx unknown
2000
- 2000-05-10 UA UA2002053825A patent/UA77153C2/uk unknown
- 2000-10-05 SI SI200030841T patent/SI1222467T1/sl unknown
- 2000-10-05 EE EEP200200189A patent/EE200200189A/xx unknown
- 2000-10-05 EP EP00968194A patent/EP1222467B1/fr not_active Expired - Lifetime
- 2000-10-05 DE DE60027031T patent/DE60027031T2/de not_active Expired - Fee Related
- 2000-10-05 DK DK00968194T patent/DK1222467T3/da active
- 2000-10-05 WO PCT/IL2000/000621 patent/WO2001027319A2/fr not_active Ceased
- 2000-10-05 PT PT00968194T patent/PT1222467E/pt unknown
- 2000-10-05 JP JP2001529450A patent/JP2003511057A/ja active Pending
- 2000-10-05 EA EA200200435A patent/EA004709B1/ru not_active IP Right Cessation
- 2000-10-05 CA CA002386365A patent/CA2386365A1/fr not_active Abandoned
- 2000-10-05 IL IL149021A patent/IL149021A/en not_active IP Right Cessation
- 2000-10-05 ES ES00968194T patent/ES2256045T3/es not_active Expired - Lifetime
- 2000-10-05 HK HK03100201.2A patent/HK1048514B/zh not_active IP Right Cessation
- 2000-10-05 BR BR0014626-9A patent/BR0014626A/pt not_active Application Discontinuation
- 2000-10-05 AT AT00968194T patent/ATE322017T1/de not_active IP Right Cessation
- 2000-10-05 US US10/110,243 patent/US7247427B1/en not_active Expired - Fee Related
- 2000-10-05 AU AU78141/00A patent/AU778727B2/en not_active Ceased
- 2000-10-05 KR KR1020027003765A patent/KR100863580B1/ko not_active Expired - Fee Related
- 2000-10-05 CN CNB008140359A patent/CN1159585C/zh not_active Expired - Fee Related
- 2000-10-09 AR ARP000105316A patent/AR025995A1/es active IP Right Grant
2002
- 2002-03-15 ZA ZA200202155A patent/ZA200202155B/en unknown
- 2002-04-04 NO NO20021604A patent/NO20021604D0/no not_active Application Discontinuation
2006
- 2006-05-04 CY CY20061100582T patent/CY1105025T1/el unknown

Also Published As

Publication number	Publication date
IL132313A0 (en)	2001-03-19
WO2001027319A2 (fr)	2001-04-19
JP2003511057A (ja)	2003-03-25
ZA200202155B (en)	2003-05-28
CA2386365A1 (fr)	2001-04-19
EE200200189A (et)	2003-06-16
DE60027031D1 (de)	2006-05-18
HK1048514B (zh)	2004-12-31
KR20020048416A (ko)	2002-06-22
US7247427B1 (en)	2007-07-24
WO2001027319A3 (fr)	2001-06-21
DK1222467T3 (da)	2006-08-07
EP1222467A2 (fr)	2002-07-17
IL149021A (en)	2007-12-03
EA200200435A1 (ru)	2002-10-31
AU778727B2 (en)	2004-12-16
PT1222467E (pt)	2006-06-30
EA004709B1 (ru)	2004-06-24
AR025995A1 (es)	2002-12-26
ES2256045T3 (es)	2006-07-16
AU7814100A (en)	2001-04-23
IL149021A0 (en)	2002-11-10
ATE322017T1 (de)	2006-04-15
KR100863580B1 (ko)	2008-10-15
CN1159585C (zh)	2004-07-28
NO20021604L (no)	2002-04-04
CY1105025T1 (el)	2010-03-03
DE60027031T2 (de)	2006-08-24
CN1378648A (zh)	2002-11-06
NO20021604D0 (no)	2002-04-04
BR0014626A (pt)	2002-06-11
EP1222467B1 (fr)	2006-03-29
HK1048514A1 (en)	2003-04-04
SI1222467T1 (sl)	2006-06-30

Publication	Publication Date	Title
Gupta et al.	2007	Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics
Coletti et al.	2002	TNFα inhibits skeletal myogenesis through a PW1‐dependent pathway by recruitment of caspase pathways
Tfelt-Hansen et al.	2006	Calcium receptor is functionally expressed in rat neonatal ventricular cardiomyocytes
US20080064040A1 (en)	2008-03-13	Monitoring gene silencing and annotating gene function in living cells
AU2008229749A1 (en)	2008-10-30	Novel compositions and methods for cancer
EA038600B1 (ru)	2021-09-21	Основанные на клетках перекрестные анализы и их применение
Ang et al.	2018	Localized visualization and autonomous detection of cell surface receptor clusters using DNA proximity circuit
EP1222467B1 (fr)	2006-03-29	Dosage de leptine base sur la detection de l'expression de l'ang-2
Sivamurthy et al.	2001	Apolipoprotein J inhibits the migration, adhesion, and proliferation of vascular smooth muscle cells
Penalva et al.	2004	RNA-binding proteins to assess gene expression states of co-cultivated cells in response to tumor cells
Pan et al.	2005	Interactions between ρ and γ2 subunits of the GABA receptor
EP1355152B1 (fr)	2010-03-03	Procédé de criblage de substances de modulation de la cascade de signaux wnt.
US5874230A (en)	1999-02-23	Assays using TRAF2-associated protein kinase polypeptides
US20050169841A1 (en)	2005-08-04	Methods of screening for B cell activity modulators
Sanchez-Carbayo et al.	2007	Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression
US20120157338A1 (en)	2012-06-21	Method for determining the risk of developing brain metastasis, and a kit to carry out said method
Burkhardt et al.	1993	Immune‐Complex Assays for Tyrosine Protein Kinases
Dummitt et al.	2006	Molecular beacons for DNA binding proteins: an emerging technology for detection of DNA binding proteins and their ligands
Tong et al.	2026	CBL proto-oncogene C-mediated synaptophysin 1 regulates prostate cancer progression in the TGF-beta signalling pathway
US20060099643A1 (en)	2006-05-11	Method for determining the regulation of xenobiotic removal
US20010046665A1 (en)	2001-11-29	Method of identifying the function of a test agent
Vandebriel	2007	Cytokine measurement tools for immunotoxicology
CN101147066A (zh)	2008-03-19	Mgc4504的用途
JPWO2006035702A1 (ja)	2008-05-15	Ｃペプチド特異的結合分子及びその用途
AU2003205900A1 (en)	2003-09-09	Screening method